Interim results from the ongoing IDeate-Lung01 phase 2 trial show that ifinatamab deruxtecan (I-DXd) continues to deliver promising objective response rates in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). These findings, part of a press conference today, will…
Eli Lilly and Company (NYSE: LLY) and EVA Pharma have announced a new partnership aimed at increasing access to baricitinib for an estimated 20,000 individuals across 49 low- and middle-income countries in Africa by 2030. Developed by Incyte and licensed…
Daiichi Sankyo Europe (Daiichi Sankyo) has reaffirmed its commitment to addressing unmet needs and barriers in cardiovascular (CV) care by highlighting disparities in treatment and outcomes among different patient groups. This announcement follows the presentation of new data from sub-analyses…
Fresenius Kabi, a division of Fresenius, and the Association for the Advancement of Blood & Biotherapies (AABB) are excited to announce the commencement of the 19th annual Blood Collectors Week, taking place from September 1 through September 7, 2024. This…
Daiichi Sankyo Europe (Daiichi Sankyo) has reinforced its commitment to addressing unmet needs and disparities in cardiovascular care by emphasizing the differences in treatment and outcomes among diverse patient groups. This announcement follows the presentation of data from the SANTORINI…
Anthos Therapeutics, Inc., a cutting-edge clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular and metabolic diseases, announced significant findings from the AZALEA-TIMI 71 study at the European Society for Cardiology (ESC) Congress. The study revealed that approximately 1%…
ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady™, is thrilled to announce that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine’s Laboratory for Cell and Gene Medicine (LCGM), has been honored with…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced that the European Commission has granted Marketing Authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment…
Merck, a leading science and technology company, has announced that the first patient has been dosed in the Phase III MyClad trial (NCT06463587). This trial aims to evaluate the efficacy and safety of oral cladribine for treating generalized Myasthenia Gravis…
GSK plc (LSE/NYSE: GSK) has announced that the European Commission has authorized Arexvy, a recombinant adjuvanted respiratory syncytial virus (RSV) vaccine, for active immunization to prevent lower respiratory tract disease (LRTD) caused by RSV in adults aged 50-59 who are…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel monoclonal antibody designed to inhibit the complement protein C5, for the treatment of adults and adolescents (12 years and older, weighing at…
Hinge Health and Midi Health have announced a partnership aimed at addressing the significant healthcare gap for women undergoing menopause. This collaboration merges Hinge Health’s expertise in movement-based support for menopause with Midi Health’s virtual care clinic, targeting the broad…